

ABBOTT LABORATORIES  
Form 8-K  
July 12, 2007

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**July 11, 2007**  
Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of registrant as specified in its charter)

**Illinois**  
(State or other Jurisdiction of Incorporation)

**1-2189**  
(Commission File Number)

**36-0698440**  
(I.R.S. Employer  
Identification No.)

---

**100 Abbott Park Road**

**Abbott Park, Illinois 60064-6400**

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(847) 937-6100**

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: ABBOTT LABORATORIES - Form 8-K

- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

-

---

**Item 1.02 Termination of a Material Definitive Agreement.**

On July 11, 2007, Abbott Laboratories announced that Abbott and General Electric Company have mutually agreed to terminate their contract for the sale of Abbott's core laboratory and point-of-care diagnostics businesses to GE. The contract was entered on January 18, 2007 and reported on a Form 8-K filed on January 24, 2007. The two companies were unable to agree on final terms and conditions of the proposed sale.

A copy of the press release announcing the termination of the contract is attached as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Exhibit No.	Exhibit
99.1	Press Release, July 11, 2007

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Abbott Laboratories**

Date: July 12, 2007

By: /s/ Thomas C. Freyman  
Thomas C. Freyman  
Executive Vice President, Finance and Chief Financial Officer

**Exhibit Index**

Exhibit No.	Exhibit
99.1	Press Release, July 11, 2007

3

---